Brief: Axcella Announces Interim Data From Phase 2b Emmpact Study Of Axa1125 In Nonalcoholic Steatohepatitis (Nash)

Axcella Health

29/09/2022 11:00

Sept 29 (Reuters) - Axcella Health Inc  AXLA.O :
    * AXCELLA ANNOUNCES INTERIM DATA FROM PHASE 2B EMMPACT STUDY
OF
AXA1125 IN NONALCOHOLIC STEATOHEPATITIS (NASH)
    * AXCELLA - SUBJECTS WITH NASH SHOWED CLINICALLY,
STATISTICALLY
SIGNIFICANT IMPROVEMENTS IN ALANINE AMINOTRANSFERASE AT BOTH
DOSE LEVELS OF AXA1125
    * AXCELLA - SUBJECTS ENROLLED WITH BIOPSY CONFIRMED NASH
EXPERIENCED CLINICALLY, STATISTICALLY SIGNIFICANT IMPROVEMENTS
IN LIVER STIFFNESS
    * AXCELLA - NUMERICAL TRENDS OF IMPROVEMENT RELATIVE TO
PLACEBO IN
PDFF SEEN AT WEEK 24 BUT NOT STATISTICALLY SIGNIFICANT IN SMALL
NUMBER OF SUBJECTS
    * AXCELLA - PHASE 2B EMMPACT STUDY FINDINGS DEMONSTRATE
IMPROVEMENT IN HEPATIC FAT AS MEASURED BY MRI-PDFF
    * AXCELLA -  AXA 1125 CONTINUES TO DEMONSTRATE A SAFE AND
WELL
TOLERATED PROFILE
    * AXCELLA -  EXPECT TO REPORT THE TOPLINE 48-WEEK BIOPSY
RESULTS
IN THE FIRST HALF OF 2024

Further company coverage:  AXLA.O 
 ((Reuters.Briefs@thomsonreuters.com))